Roivant’s Priovant gained FDA clearance for Lisraya (brepocitinib), an oral JAK1/TYK2 inhibitor, to treat dermatomyositis. The approval marks a major regulatory milestone for the hub-and-spoke autoimmune strategy built around brepocitinib’s rare-disease focus, with the drug now able to move through commercial launch planning. According to the FDA decision coverage, Lisraya is positioned as an alternative to high-dose steroids and other immunosuppressive regimens that have been the standard of care for dermatomyositis. Roivant has described dermatomyositis as affecting roughly 40,000 to 70,000 people in the U.S., underscoring the addressable population for this label. The next gating item is how quickly clinicians translate the new oral option into treatment algorithms, and whether additional autoimmune indications in Priovant’s program pipeline gain momentum alongside early uptake.